New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Paesmans, 1997, Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party, Eur J Cancer, 33, 2326, 10.1016/S0959-8049(97)00325-0

Buyse, 2000, Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis group in Cancer, Lancet, 356, 373, 10.1016/S0140-6736(00)02528-9

Goffin, 2005, Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval, Clin Cancer Res, 15, 5928, 10.1158/1078-0432.CCR-05-0130

El-Maraghi, 2008, Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III, J Clin Oncol, 10, 1346, 10.1200/JCO.2007.13.5913

Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

Tonkin, 1985, Criteria of tumor response used in clinical trials of chemotherapy, J Clin Oncol, 3, 870, 10.1200/JCO.1985.3.6.870

Baar, 1989, Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials, J Clin Oncol, 7, 969, 10.1200/JCO.1989.7.7.969

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines), J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Therasse, 2006, RECIST revisited: a review of validation studies on tumour assessment, Eur J Cancer, 42, 1031, 10.1016/j.ejca.2006.01.026

Bogaerts, 2009, Individual patient data analysis to assess modifications to the RECIST criteria, Eur J Cancer, 45, 248, 10.1016/j.ejca.2008.10.027

Moskowitz, 2009, A simulation study to evaluate the impact of the number of lesions measured on response assessment, Eur J Cancer, 45, 300, 10.1016/j.ejca.2008.11.010

Sargent, 2009, Validation of novel imaging methodologies for use as cancer clinical trials end-points, Eur J Cancer, 45, 290, 10.1016/j.ejca.2008.10.030

Macdonald, 1990, Response criteria for phase II studies of supratentorial malignant glioma, J Clin Oncol, 8, 1277, 10.1200/JCO.1990.8.7.1277

Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 10, 579, 10.1200/JCO.2006.09.2403

Schwartz, 2009, Evaluation of lymph nodes with RECIST 1.1, Eur J Cancer, 45, 261, 10.1016/j.ejca.2008.10.028

Rustin, 2004, Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer), J Natl Cancer Inst, 96, 487, 10.1093/jnci/djh081

Bubley, 1999, Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol, 17, 3461, 10.1200/JCO.1999.17.11.3461

Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487

Vergote, 2000, Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup, J Natl Cancer Inst, 92, 1534, 10.1093/jnci/92.18.1534

Van Glabbeke, 2002, EORTC Soft Tissue and Bone Sarcoma Group: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas, Eur J Cancer, 38, 543, 10.1016/S0959-8049(01)00398-7

Dancey, 2009, Recommendations for the assessment of progression in randomised cancer treatment trials, Eur J Cancer, 45, 281, 10.1016/j.ejca.2008.10.042

Ford, 2009, Lessons learned from independent central review, Eur J Cancer, 45, 268, 10.1016/j.ejca.2008.10.031

Catalano, 2007, Optimizing radiation dose and image quality, Eur Radiol, 17, F26, 10.1007/s10406-007-0225-6

Low, 2007, Abdominal MRI advances in the detection of liver tumours and characterization, Lancet Oncol, 8, 525, 10.1016/S1470-2045(07)70170-5

Barrett, 2006, Imaging of the lymphatic system: new horizons, Contrast Media Mol Imaging, 1, 230, 10.1002/cmmi.116

Shankar, 2006, National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials, J Nucl Med, 47, 1059